Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity

International Journal of Biological Sciences

Volumn 7, Issue 5, 2011, Pages 618-628

  Li, Weina ^a   Song, Liqiang ^b   Wu, Shouzhen ^a   Xue, Xiaochang ^a   Zhang, Lu ^a   He, Liqing ^a   Han, Wei ^a   Wang, Qing ^c   Ling, Rui ^a   Zhang, Wei ^a   Yan, Zhen ^a   Zhang, Yingqi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Concatemer; Protein expression; Purification; Thymosin alpha 1; Tumor suppression

Indexed keywords

ESCHERICHIA COLI; MUS;

EID: 79960136040     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.618     Document Type: Article

References (36)

1. Goldstein Al, Low TL, McAdoo M, et al. Thymosin alpha l: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. 1977; 74(2):725-729.
2. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am. J. Health Syst. Pharm. 2001; 58(10):879-885.
3. Sztein MB, Goldstein AL. Thymic hormones--a clinical update. Springer Semin Immunopathol. 1986;9:1-18.
4. Goldstein AL, Badamchian M. Thymosins: chemistry and bio-logical properties in health and disease. Expert Opin Biol Ther. 2004; 4(4):559.
5. Chen C, Li M, Yang H, et al. Roles of thymosins in cancers and other organ systems. World J. Surg. 2005; 29(3): 264-270.
6. Baumann CA, Badamchian M, Golstein AL. Thymosin α1 an-tagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mechanism of Ageing and Development. 1997; 94:85-101.
7. Roy R, Singh SM, Shanker A. Mechanism of thymocyte apop-tosis induced by serum of tumor-bearing host: The molecular events involved and their inhibition by thymosin α-1. Int. J. Immunopharmacol. 2000; 22: 309-321.
8. Wolf GT, Hudson J, Peterson KA, et al. Interleukin 2 receptor expression in patients with head and neck squamous carcino-ma.Effects of thymosin alpha 1 in vitro. Arch. Otolaryngol Head Neck Surg. 1989;115:1345-9.
9. Ying-zhe Fan, Hui Chang, Ye Yu, et al. Thymosin alpha1 sup-presses proliferation and induces apoptosis in human leukemia cell lines. Peptides. 2006;27(9): 2165-2173.
10. Spangelo BL, et al. Presence of a peptide component of thymo-sin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells. International Im-munopharmacology. 2005; 5(7-8): 1317-1329.
11. Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung can-cer cells in vitro and in vivo. Cancer Res. 1993; 53: 5214-8.
12. Hadden JW. Thymic Endocrinology. Annals of the New York Academy of Sciences. 1998;840: 352-358.
13. Low TL, et al. The chemistry and biology of thymosin. J. Biol. Chem. 1979;254:981-986.
14. Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus. 1984; 6: 27-42.
15. Li CL, Zhang T, Saibara T, et al. Thymosin alpha 1 accelerates restoration of T-cell-mediated neutralizing antibody response in immunocompromised hosts. Int. Immunopharma-col.2002;2:39-46.
16. Hadden JW. Immunodeficiency and cancer: prospects for cor-rection. Int Immunopharmacol.2003;3:1061-71.
17. Garaci E, Pica F, Rasi G, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int. J. Immunopharmacol. 2000; 22: 1067-76.
18. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. Gastroenterol Hepatol. 2002;17:409-14.
19. Chadwick D, Pido-Lopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmentingimmune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol. 2003;134:477-81.
20. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol. 2003;3:1145-50.
21. Billich A. Thymosin α1(SciClone Pharmaceuticals) Current Opioion in Investigational. Drugs. 2002;3: 698-707.
22. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 1998;18:3571-3578.
23. Moody TW, Tuthill C, Badamchian M, et al. Thymosin alpha1 inhibits mammary carcinogenesis in Fisher rats. Peptides. 2002;23: 1011-1014.
24. Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al. Combination therapy in the treatment of chronic viral hepatitis and preven-tion of hepatocellular carcinoma. Int. Immunopharmacol. 2003; 3: 1169-1176.
25. An TT, Liu XY, Fang J. Primary assessment of treatment effect of thymosin alpha1 on chemotherapy-induced neurotoxicity. Ai Zheng. 2004;23(11): 1428-30.
26. Qiong Shen, Ruiyang Tian, Wenzhe Ma. Construction and expression of a new fusion protein, thymosin a1-cBLyS in E.coli. Biotechnology Letters. 2005; 27: 143-148.
27. Zhou L, Lai ZT, Lu MK, et al. Expression and Hydroxylamine Cleavage of Thymosin Alpha 1 Concatemer. Journal of Bio-medicine and Biotechnology. 2008;2008:736060.
28. You-Feng Yang, Han-Ying Yuan, Nan-Song Liu. Construction, expression and characterization of human interferon α2b-(G4S)n-thymosin α1 fusion proteins in Pichia pastoris. World J. Gastroenterol. 2005;11:2597-2602.
29. Pei-Fu CHEN, Hong-Ying ZHANG, Geng-Feng FU. Overex-pression of Soluble Human Thymosin Alpha 1 in Escherichia coli. Acta. Biochim. Biophys. Sin. (Shanghai). 2005;37:147-151.
30. Chen Y, Zhao L, Shen G, et al. Expression and analysis of thy-mosin α1 concatemer in Escherichia coli. Biotechnol. Appl. Bi-ochem. 2008;49:51-56.
31. Yong Qin, Fu-Ding Chen, Liang Zhou, et al. Proliferative and anti-proliferative effects of thymosin α1 on cells are associated with manipulation of cellular ROS levels. J. Chemico-biological Interactions. 2009;180:383-8.
32. Low TL, McClure JE, Naylor PH, et al. Isolation of thymosin alpha 1 from thymosin fraction 5 of different species by high-performance liquid chromatography. J. Chromatogr. 1983;26:533-44.
33. Danho W, Gabriel TF, Makofske RC. Isolation and identifica-tion of thymosin alpha 1 from calf spleen using high perfor-mance liquid chromatography. Int. J. Pept. Protein Res. 1984;23:630-6.
34. Wang SS, Makofske R, Bach A, et al. Automated solid phase synthesis of thymosin alpha 1. Int. J. Pept. Protein Res. 1980;15:1-4.
35. Wong TW, Merrifield RB. Solid-phase synthesis of thymosin alpha 1 using tert-butyloxycarbonylaminoacyl-4-(oxymethyl) phenylacetamidomethyl-resin. Biochemistry. 1980;19:3233-8.
36. Allan L Goldstein, Adsm L Goldstein. From lab to bedside: emerging clinical applications of thymosin α1. Expert. Opin. Biol. Ther. 2009;9:593-608.